Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935336 · ClinicalTrials.gov registry record · Phase 2
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT01935336 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 171 participants.
The verdict
NCT01935336, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Ponatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2013-09-24 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935336
The ClinicalTrials.gov registry entry for NCT01935336 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ponatinib is the first listed.
NCT01935336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01935336 about?
NCT01935336 is a clinical study titled "Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers". This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01935336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2013-09-24. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01935336?
The interventions under investigation include: Ponatinib (DRUG).
Who is sponsoring clinical trial NCT01935336?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.